These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9973270)

  • 1. Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold.
    Paulson HL
    Am J Hum Genet; 1999 Feb; 64(2):339-45. PubMed ID: 9973270
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent advances in understanding the pathogenesis of polyglutamine diseases: involvement of molecular chaperones and ubiquitin-proteasome pathway.
    Jana NR; Nukina N
    J Chem Neuroanat; 2003 Oct; 26(2):95-101. PubMed ID: 14599658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation.
    Schaffar G; Breuer P; Boteva R; Behrends C; Tzvetkov N; Strippel N; Sakahira H; Siegers K; Hayer-Hartl M; Hartl FU
    Mol Cell; 2004 Jul; 15(1):95-105. PubMed ID: 15225551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The attention of researchers on the biological process of protein folding has turned to the formation and properties of aggregates.
    Ellis RJ
    Semin Cell Dev Biol; 2004 Feb; 15(1):1-2. PubMed ID: 15036201
    [No Abstract]   [Full Text] [Related]  

  • 5. Conformational changes and aggregation of expanded polyglutamine proteins as therapeutic targets of the polyglutamine diseases: exposed beta-sheet hypothesis.
    Nagai Y; Popiel HA
    Curr Pharm Des; 2008; 14(30):3267-79. PubMed ID: 19075705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein.
    Fu L; Gao YS; Sztul E
    Neurobiol Dis; 2005 Dec; 20(3):656-65. PubMed ID: 15964198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Mechanism of polyglutamine aggregate formation].
    Kimura Y
    Tanpakushitsu Kakusan Koso; 2004 May; 49(7 Suppl):1122-3. PubMed ID: 15168544
    [No Abstract]   [Full Text] [Related]  

  • 8. Analyzing the aggregation of polyglutamine-expansion proteins and its modulation by molecular chaperones.
    Kubota H; Kitamura A; Nagata K
    Methods; 2011 Mar; 53(3):267-74. PubMed ID: 21195182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pathomechanism of polyglutamine diseases and strategic design for their therapies].
    Nukina N
    Rinsho Shinkeigaku; 2008 Nov; 48(11):913-4. PubMed ID: 19198116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The protein quality control and neurodegeneration].
    Tanaka K; Murata S
    Nihon Yakurigaku Zasshi; 2003 Jul; 122(1):30-6. PubMed ID: 12843570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular chaperones biochemistry and role in neurodegenerative diseases.
    Chaari A
    Int J Biol Macromol; 2019 Jun; 131():396-411. PubMed ID: 30853582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Molecular mechanisms of neurodegeneration in polyglutamine diseases].
    Tsuji S
    Nihon Ronen Igakkai Zasshi; 2007 Mar; 44(2):154-7. PubMed ID: 17539196
    [No Abstract]   [Full Text] [Related]  

  • 13. [Quality control mechanism of proteins and cellular crisis management].
    Nagata K
    Tanpakushitsu Kakusan Koso; 2004 May; 49(7 Suppl):973-83. PubMed ID: 15168507
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis.
    Wyttenbach A
    J Mol Neurosci; 2004; 23(1-2):69-96. PubMed ID: 15126694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic opportunities in polyglutamine disease.
    Hughes RE; Olson JM
    Nat Med; 2001 Apr; 7(4):419-23. PubMed ID: 11283667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyglutamine diseases: protein cleavage and aggregation.
    Zoghbi HY; Orr HT
    Curr Opin Neurobiol; 1999 Oct; 9(5):566-70. PubMed ID: 10508741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neurodegenerative disorders as protein misfolding diseases and organelle diseases].
    Kakizuka A; Mori M
    Tanpakushitsu Kakusan Koso; 2004 May; 49(7 Suppl):1077-85. PubMed ID: 15168533
    [No Abstract]   [Full Text] [Related]  

  • 18. [Toxic conformer of the polyglutamine protein].
    Nagai Y
    Tanpakushitsu Kakusan Koso; 2008 Mar; 53(3):235-41. PubMed ID: 18326296
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of molecular chaperones in neurodegenerative disorders.
    Meriin AB; Sherman MY
    Int J Hyperthermia; 2005 Aug; 21(5):403-19. PubMed ID: 16048838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of chaperones in polyglutamine disease.
    Opal P; Zoghbi HY
    Trends Mol Med; 2002 May; 8(5):232-6. PubMed ID: 12067633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.